Genomics
PrivateA pre-revenue proteomics-tools optionality call dressed up as a "below cash" trade — at ~$2/share the net-cash floor is GONE (it re-rated to ~2x net cash) and you are now paying for a single-molecule platform that has placed exactly one customer (Baylor) and won't ship instruments until early 2027; bet on execution, not on the balance sheet.
Research
The verdict
A pre-revenue proteomics-tools optionality call dressed up as a "below cash" trade — at ~$2/share the net-cash floor is GONE (it re-rated to ~2x net cash) and you are now paying for a single-molecule platform that has placed exactly one customer (Baylor) and won't ship instruments until early 2027; bet on execution, not on the balance sheet.
Primary sources
Source documents — open to read in full
What it is. Nautilus is a Seattle-HQ'd (R&D in San Carlos, CA), 2016-founded, development-stage life-sciences-tools company building the Nautilus Voyager™ platform — an end-to-end single-molecule proteomics system (instrument + consumables/flow cells + affinity reagents + cloud/ML software) that implements its proprietary "Iterative Mapping" method. The pitch: comprehensively measure the proteome — both broadscale (the ~20,000 canonical human proteins) and targeted proteoform analysis (functional variants/PTMs, estimated at ~6,000,000 proteoforms) — with breadth + depth + reproducibility that today's mass-spec and affinity methods can't deliver together.
How it intends to make money (none of this is live yet): a classic life-science-tools razor/razor-blade model — sell a high-end instrument (priced "comparable to high-end mass-spec budgets"), then recurring consumables (flow cells, ~300 unique multi-affinity reagents/antibodies), service, support and software. Entry is land-and-expand: start with a fee-for-service model (Nautilus runs samples in-house), then place instruments at customer sites.
Where it is on the curve. Pre-revenue. Zero product revenue since inception. The only income line is interest income on the cash pile ($7.9M FY25; $1.4M Q1-26). Commercial sequencing of events (management's own timeline):
Customers / partners. Research collaborations (research-only, not revenue-generating): Genentech (Dec 2020), The Buck Institute for Research on Aging (Feb 2025), Michael J. Fox Foundation + Weill Cornell Medicine–Qatar (Jan 2026), Allen Institute (Jul 2025); plus the first paying-ish EAP logo, Baylor. customers.csv is empty — there is no revenue concentration because there is no revenue.
Heritage / structure. Public since June 2021 via SPAC merger with ARYA Sciences Acquisition Corp III ($200M PIPE at $10.00/share; ~$345.5M gross from the deal). This is a busted-SPAC that traded from $10 → sub-$1 → partial recovery. 130 employees (91 R&D / 39 G&A), >1/3 PhDs.
supply-chain.md is missing in the commercial layer, so this is built from the filings — which are unusually candid about chokepoints.
Upstream inputs → Nautilus → end customer:
Chokepoints (named): (1) single-source nanoarray chips (already bit them); (2) the ~300-reagent/antibody manufacturing scale-up; (3) long-lead cameras/lasers; (4) unproven co-development partner deliverables. Names or it didn't happen: the filings name the categories and the customer/partner entities (Genentech, Buck, Allen, MJFF, WCM-Q, Baylor) but do not name the specific chip foundry or reagent vendors — n/a — not disclosed at the vendor level.
positioning.md/bottlenecks.md missing — built from filings + web.
The claimed moat (3 layers):
Bargaining power — who needs whom more? Today, Nautilus needs everyone more than they need it. It has no installed base, no publications-led KOL endorsement at scale, no revenue, and is negotiating against giants for collaborations "where we may have relatively less leverage" (its own words). Switching costs / network effects / scale advantages — all prospective, none realized. The honest read: the moat is latent in the IP + architecture, and will only become an economic moat if the box ships, performs in customers' hands, and gets cited in peer-reviewed journals. Until then it is a science project with a patent wall.
Durability risk: the most dangerous competitive fact is that the incumbents are not standing still and are vastly better capitalized (see Lens 13).
Hard limit: Nautilus reports one operating and one reportable segment, and the CODM (the CEO) reviews financials on a consolidated basis. All long-lived assets are US-based. segments.csv is empty.
So there is no product or geographic revenue to break out — because revenue is $0. The only meaningful "segmentation" is the expense split, which is the story of FY2025: a deliberate cost rationalization.
| Line | FY2024 | FY2025 | Δ | Source |
|---|---|---|---|---|
| R&D expense | $50.5M | $41.1M | −19% | |
| G&A expense | $31.0M | $25.7M | −17% | |
| Total opex | $81.5M | $66.8M | −18% | |
| Net loss | $(70.8)M | $(59.0)M | −17% |
Driver: a Q1-2025 reduction-in-force plus lower SBC (Merger-era options fully expensing) and lab-supply efficiencies. Direction = decelerating burn — management chose runway preservation over growth spend ahead of launch. Note the tension: management guides opex to "increase substantially" post-launch (sales/marketing/manufacturing build) — so FY2025's discipline is a pre-launch trough, not a new structural level.
Latest print: Q1 2026 (qtr ended Mar 31, 2026; 10-Q filed Apr 28, 2026).
| Metric | Q1-2026 | Q1-2025 | YoY | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | — | |
| R&D | $9.7M | $11.5M | −16% | |
| SG&A | $6.4M | $7.3M | −12% | |
| Total opex | $16.1M | $18.8M | −14% | |
| Interest income | $1.4M | $2.2M | −35% | |
| Net loss | $(14.7)M | $(16.6)M | −12% | |
| EPS | $(0.12) | $(0.13) | — | |
| Operating cash burn | $(13.1)M | $(13.9)M | −6% |
vs. consensus: EPS −$0.12 beat the −$0.14 estimate by ~2c. For a pre-revenue tools company a "beat" just means burn came in a hair light — it is not a demand signal.
Balance sheet (Mar 31, 2026):
Flags vs. its own history: none alarming — burn is falling, the RIF is annualizing through, and importantly they did NOT tap the ATM in Q1-2026 (0 shares sold). The "deceleration" is in expenses, not in a revenue line that doesn't exist.
Market reaction: the print itself was a non-event; the stock's 2026 move (~$0.78 → ~$2-3) is a recovery-of-optionality re-rate tied to the Voyager unveil + Baylor logo, not to numbers.
transcripts/ is empty on the shelf (none ingested) — so this lens is ``-grounded and necessarily thinner than ideal.
Tone shift over time: the recurring 2024-2025 message was "patience — this is incredibly ambitious" (the CEO literally framed it as needing investor patience ). Through 2026 the vocabulary shifted to launch logistics (pre-orders, installs, EAP logos, assay portfolio). What they've stopped saying: open-ended "development-stage" hedging is giving way to dated milestones. What they keep saying, conspicuously: "we do not anticipate material revenue" from EAP — management is actively managing expectations down on near-term revenue while pointing at 2027. Caveat: with no transcripts on the shelf, this sentiment read is summary-derived and should be re-grounded by ingesting the Fool/Insider-Monkey Q4-25 and Q1-26 transcripts on the next pass.
| Company | Ticker | Mkt cap (≈, Jun 2026) | Net cash (≈) | EV (≈) | EV/Sales · P/E | What it is | Source |
|---|---|---|---|---|---|---|---|
| Nautilus | NAUT | ~$255–305M | ~$143M (no debt) | ~$110–160M | n/a — pre-revenue | Single-molecule iterative-mapping proteomics; pre-launch | ; cash |
| Quantum-Si | QSI | ~$180–257M | n/a (sizeable; SPAC cash) | n/a | n/a — pre-revenue (~$1M 2026 guide) | Next-gen protein sequencing (Proteus); EAP summer-26, launch end-26 | |
| Quanterix | QTRX | ~$165M | ~$103M cash | ~$60M | n/a — has revenue but loss-making; ~breakeven H2-26 target | Simoa single-molecule immunoassay (revenue-generating incumbent) | |
| Seer | SEER | n/a | (large; SPAC cash) | n/a | n/a — minimal revenue | Proteograph broadscale (nanoparticle) — closest broadscale peer | |
| Thermo Fisher (Olink) | TMO | mega-cap | — | — | n/a here (Olink = a unit) | Olink PEA (5,400-plex), UK Biobank — the gorilla; TMO bought Olink for $3.1B (Jul 2024) | |
| Bruker / Agilent / Danaher(SCIEX) / BD | — | mega/large-cap | — | — | n/a here | Mass-spec & affinity incumbents named as NAUT competitors |
Read: the cleanest peer is Quantum-Si — almost identical archetype (busted-SPAC single-molecule-protein platform, EAP-then-launch in the same end-2026/2027 window, ~$1M of near-term revenue, sub-$300M cap). NAUT and QSI are essentially two lottery tickets on the same de-novo-protein-measurement bet at the same maturity, trading at similar caps. Quanterix is the "what good looks like with revenue" anchor — and tellingly it trades at an EV of only ~$60M despite shipping product and nearing breakeven, which caps how much the market is willing to pay for proteomics-tools stories right now. NAUT's ~$110-160M EV is therefore richer than a revenue-generating peer's EV — a yellow flag on valuation (Lens 12).
Mostly ``; the pattern is stark.
What the tape reveals: NAUT trades on two things only — runway survival and commercialization-milestone credibility. It is not an earnings stock (no earnings), not a macro stock except insofar as risk-appetite/biotech-funding sentiment gates micro-cap pre-revenue names. The >5% moves cluster on: cash-runway disclosures, platform/assay reveals, named customer wins, insider buying, and analyst rating changes. It is a binary-catalyst, sentiment-and-survival instrument — which also means it is brutally exposed to any commercialization slip (the same lever in reverse).
CEO / co-founder: Sujal Patel. The headline asset on the team. Founder/CEO of Isilon Systems, which he took public and sold to EMC for ~$2.25B in 2010 — a genuine, large, realized technology exit. He is President, CEO & Secretary and owns ~17.4M shares (~10%+ of the company; a meaningfully larger % of the float). Crucially, he has been buying NAUT in the open market (disclosed purchases Mar 5, 2026 and around that window) — a founder adding to an already-large stake near multi-year lows is the strongest alignment signal in this file. He also received a 650,000-option award.
Co-founder / Chief Scientist & Director: Parag Mallick — Stanford proteomics researcher; the scientific architect of Iterative Mapping (signed the 10-K as a director).
CFO: Anna Mowry (Principal Financial & Accounting Officer). Plus Subra Sankar among named officers.
Board/exec pedigree: the team and board carry leadership experience from Illumina, Agilent, Yahoo!, Isilon — deliberately a genomics-tools + data/tech hybrid, which fits the "single-molecule data → AI training" thesis.
Scientific Advisory Board — genuinely elite: Ruedi Aebersold (ETH Zurich, proteomics pioneer / Human Proteome Project), Lee Hartwell (Nobel laureate, Physiology/Medicine 2001), Joshua LaBaer (ASU Biodesign), Emma Lundberg (Stanford/KTH, Human Protein Atlas). This is not a vanity SAB; these are field-defining names, which matters for the publications-led adoption path.
Capital allocation track record: mixed-to-prudent for the stage. They burned ~$59M in FY25 but cut burn 18% and preserved a ~$143M war chest with no debt and no dilution at depressed prices (ATM untouched) — disciplined stewardship of a SPAC windfall. The negative: this is a team that has spent ~$346.7M of accumulated deficit over ~10 years and still has zero revenue — the ultimate verdict on capital allocation here is deferred until the box sells.
Founder vs. professional manager: founder-led, founder-aligned (Patel + Mallick), which is the right archetype for a long-horizon, scientifically-ambitious platform bet. Red flags: none of the classic ones (no related-party self-dealing, no promotional behavior in the filings, comp not egregious for a SPAC-era biotech, RIF shows willingness to make hard calls). The honest risk is founder optimism / timeline risk, not founder integrity.
Acting as a forensic analyst across the three statements — and the good news for a forensic lens is that a pre-revenue company has very little surface for accounting games (no revenue to recognize aggressively, no receivables to stuff, no channel to stuff into).
Regulatory findings (required sub-section).
regulatory/regulatory-findings.md reports total_sec_findings: 0 across EDGAR EFTS (LR + AAER) for the 2021-06-29 → 2026-06-29 window.Forensic bottom line: the books are clean and conservative. The risk in NAUT is emphatically not accounting — it is commercial execution and dilution timing. The one thing a forensic eye should pre-commit to watching: the moment revenue starts (2027), scrutinize how aggressively service/instrument revenue is recognized and whether inventory/receivables outrun it.
There is no revenue to build an EPS bridge from — so the projection that matters is does the cash reach the value-inflection catalysts, and what is the dilution math? (No forecast.ts create is logged — this is the --watchlist loop, and there's no committed EPS base case to score.)
Runway math (base case):
The catalyst that actually matters (the Brier-style binary to watch, not logged here): "NAUT ships Voyager instruments to paying customers (first installs) by mid-2027 with reproducible third-party-validated performance." If yes → the platform is real and the cash floor matters again as a margin of safety. If the late-2026 pre-order / early-2027 install timeline slips (and this company has a history of timeline slips and co-development-partner delivery problems), the stock re-rates back toward cash and the dilution clock speeds up.
Valuation framing (not a price target build): at ~$2.00-2.40 the market is paying an EV of ~$110-160M for the platform optionality on top of ~$143M cash. For reference, revenue-generating Quanterix carries an EV of only ~$60M. So NAUT is not cheap on optionality at these levels — the easy "below net cash" trade that existed at $0.62-$1.00 in early 2025 is gone.
Bull case. This is the only commercial platform designed to do what proteomics most wants and can't yet do — broadscale + proteoform-level depth + reproducibility on one box — backed by a serious IP wall (36 issued US patents), a Nobel-grade SAB, and a proven repeat-builder/exited founder (Isilon → $2.25B) who is buying his own stock near lows. The balance sheet is pristine: $143M, no debt, ATM untouched, 2.7yr runway, burn falling 18%. 2026 finally turned the narrative from "science project" to "launch" — Voyager unveiled at HUPO, first EAP customer (Baylor) named, Tau/Alzheimer's assay live, pre-orders late-2026, installs early-2027. The proteomics TAM is real ($57B by 2030, ~13% CAGR per BCC) and 16,000+ installed mass-spec instruments are the replacement pool. If the box performs in customers' hands and gets cited, this is a multi-bagger from a sub-$300M cap — and the downside is partly cushioned by ~$1.14/share of net cash.
Bear case (2–3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke — what happened?): Voyager pre-orders slipped from "late 2026" into 2027, first installs revealed reproducibility/performance gaps vs. spec in customers' hands (not just in-house), reagent manufacturing couldn't scale to ~300 SKUs at quality/cost, NIH-squeezed academics deferred capital purchases, the company tapped the ATM at a low price to extend runway → dilution + lost-credibility → stock back to/below net cash. All of these are in the filings as named risks, and the timeline-slip leg has historical precedent.
Is the multiple too high? On optionality, arguably yes — paying a ~$110-160M EV (above revenue-generating Quanterix's ~$60M EV) for a platform that hasn't shipped is rich. The bull retort: you're buying the only proteoform-depth box + cash cushion, and the EV is small in absolute terms for the size of the prize.
Contrarian view (what the market refuses to see): the consensus frames NAUT as a binary "does the science work" lottery ticket. The contrarian read is that the more durable value is the founder + IP + clean balance sheet as an acquisition substrate: a $143M-cash, no-debt, single-molecule-proteoform IP estate run by a proven exited founder is exactly the kind of bolt-on a Thermo/Danaher/Illumina could buy cheaply if the box half-works — the floor may be an M&A floor, not just a cash floor.
Dismantling the bull case.
Short-seller's honest caveat: the ~$143M cash / $1.14 book and a buying founder make NAUT a dangerous short on valuation — you can be right on the science doubt and still get run over by a sentiment/optionality squeeze (the 52-wk range is $0.62→$4.31). This is a "fade the optimism into milestone dates, don't naked-short the cash floor" situation.
The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to.
A genuinely profitable, self-funded in-vivo gene-therapy platform whose entire growth narrative now rests on ex-US VYJUVEK launches (US is flat) plus an unhedged binary KB707/NSCLC option — priced at ~23x sales as if both already work.
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.